Αποτελέσματα αναζήτησης - David Fabrizio

Περιορισμός αποτελεσμάτων
  1. 1
    Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies

    Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies από Ryan J. Hartmaier, Jehad Charo, David Fabrizio, Michael E. Goldberg, Lee A. Albacker, William Pao, Juliann Chmielecki

    Έκδοση 2017
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  2. 2
    Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

    Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence από Samuel J. Klempner, David Fabrizio, Shalmali Bane, Marcia Reinhart, Tim Peoples, Siraj M. Ali, Ethan S. Sokol, Garrett M. Frampton, Alexa B. Schrock, Rachel Anhorn, Prasanth Reddy

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Revisão
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  3. 3
    DRAGON: A Member of the Repulsive Guidance Molecule-Related Family of Neuronal- and Muscle-Expressed Membrane Proteins Is Regulated by DRG11 and Has Neuronal Adhesive Properties

    DRAGON: A Member of the Repulsive Guidance Molecule-Related Family of Neuronal- and Muscle-Expressed Membrane Proteins Is Regulated by DRG11 and Has Neuronal Adhesive Properties από Tarek A. Samad, Ashok Srinivasan, Laurie A. Karchewski, Sung‐Jin Jeong, Jason Campagna, Ru‐Rong Ji, David Fabrizio, Ying Zhang, Herbert Y. Lin, Esther Bell, Clifford J. Woolf

    Έκδοση 2004
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  4. 4
    Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

    Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma από Celina Ang, Samuel J. Klempner, Siraj M. Ali, Russell W. Madison, Jeffrey S. Ross, Eric A. Severson, David Fabrizio, Aaron M. Goodman, Razelle Kurzrock, James Suh, Sherri Z. Millis

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  5. 5
    Prevalence of<i>PDL1</i>Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

    Prevalence of<i>PDL1</i>Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors από Aaron M. Goodman, David Piccioni, Shumei Kato, Amélie Boichard, Huan‐You Wang, Garrett M. Frampton, Scott M. Lippman, Caitlin Connelly, David Fabrizio, Vincent A. Miller, Jason K. Sicklick, Razelle Kurzrock

    Έκδοση 2018
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  6. 6
    Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

    Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors από Changxia Shao, Gerald Li, Lingkang Huang, Scott K. Pruitt, Emily Castellanos, Garrett M. Frampton, Kenneth R. Carson, Tamara Snow, Gaurav Singal, David Fabrizio, Brian M. Alexander, Fan Jin, Wei Zhou

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  7. 7
    Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

    Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population από C. Benedikt Westphalen, Matthew Krebs, C. Le Tourneau, Ethan Sokol, Sophia L. Maund, Timothy R. Wilson, Dexter X. Jin, Justin Y. Newberg, David Fabrizio, L. Véronèse, M. Thomas, Filippo de Braud

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  8. 8
    High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

    High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers από Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Sharabi, Shumei Kato, Razelle Kurzrock

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  9. 9
    DRAGON, a Bone Morphogenetic Protein Co-receptor

    DRAGON, a Bone Morphogenetic Protein Co-receptor από Tarek A. Samad, Anuradha Rebbapragada, Esther Bell, Ying E. Zhang, Yisrael Sidis, Sung‐Jin Jeong, Jason Campagna, Stephen Perusini, David Fabrizio, Alan L. Schneyer, Herbert Y. Lin, Ali H. Brivanlou, Liliana Attisano, Clifford J. Woolf

    Έκδοση 2005
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  10. 10
    Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

    Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) από David R. Gandara, Marcin Kowanetz, Tony Mok, Achim Rittmeyer, Louis Fehrenbacher, David Fabrizio, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Sarah Paul, Lukas C. Amler, Todd Riehl, Erica Schleifman, Craig Cummings, P. Hegde, Wei Zou, Anna Sandler, M. Ballinger, David S. Shames

    Έκδοση 2017
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  11. 11
    Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i>

    Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> από Jeffrey S. Ross, Marwan Fakih, Siraj M. Ali, Julia A. Elvin, Alexa B. Schrock, James Suh, Jo‐Anne Vergilio, Shakti Ramkissoon, Eric A. Severson, Sugganth Daniel, David Fabrizio, Garrett M. Frampton, James Sun, Vincent A. Miller, Philip J. Stephens, Laurie M. Gay

    Έκδοση 2018
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  12. 12
    Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition

    Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition από David Fabrizio, Thomas J. George, Richard F. Dunne, Garrett M. Frampton, James Sun, Kyle Gowen, Mark Kennedy, Joel Greenbowe, Alexa B. Schrock, Aram F. Hezel, Jeffrey S. Ross, P. J. Stephens, Siraj M. Ali, Vincent A. Miller, Marwan Fakih, Samuel J. Klempner

    Έκδοση 2018
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  13. 13
    A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples

    A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient S... από Sally E. Trabucco, Kyle Gowen, Sophia L. Maund, Eric M. Sanford, David Fabrizio, Michael J. Hall, Evgeny Yakirevich, Jeffrey P. Gregg, Phil Stephens, Garrett M. Frampton, Priti S. Hegde, Vincent A. Miller, Jeffrey S. Ross, Ryan J. Hartmaier, Shih-Min A. Huang, James Sun

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  14. 14
    Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

    Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial από Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  15. 15
    Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

    Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors από Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell W. Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan Sokol, Sai‐Hong Ignatius Ou, Zhen Shi

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  16. 16
    A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

    A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer από Zoe J. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  17. 17
    Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer

    Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer από Christopher J. Sweeney, Russell Petry, Chang Xu, Merrida Childress, Jie He, David Fabrizio, Ole Gjoerup, Samantha Morley, Timothy Catlett, Zoe J. Assaf, Kobe Yuen, Matthew Wongchenko, Kalpit Shah, Pratyush Gupta, Priti Hegde, Lincoln W. Pasquina, Sanjeev Mariathasan, Ryon P. Graf, Thomas Powles

    Έκδοση 2024
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  18. 18
    Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies

    Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies από Jeffrey S. Ross, Laurie M. Gay, K. Wang, Jo‐Anne Vergilio, James Suh, Shakti Ramkissoon, Hilary Somerset, Jennifer M. Johnson, Jeffery S. Russell, Siraj M. Ali, Alexa B. Schrock, David Fabrizio, Garrett M. Frampton, V.A. Miller, Philip J. Stephens, Julia A. Elvin, Daniel W. Bowles

    Έκδοση 2017
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  19. 19
    Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

    Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L no... από Mark A. Socinski, Vamsidhar Velcheti, Tarek Mekhail, Y.K. Chae, Ticiana Leal, J.E. Dowell, Ming-Hung Tsai, Christopher Dakhil, Philip J. Stella, Vincent K. Shen, Sylvia Hu, S.M. Paul, David S. Shames, Erica Schleifman, David Fabrizio, Michaeł Nowicki, C. Yun, S. Phan, E.S. Kim

    Έκδοση 2019
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  20. 20
    A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer

    A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer από Kuei‐Ting Chen, Russell W. Madison, Jay A. Moore, Dexter X. Jin, Zoë Fleischmann, Justin Y. Newberg, Alexa B. Schrock, Neeru Bhardwaj, Katherine T Lofgren, Jie He, Garrett M. Frampton, Priti Hegde, David Fabrizio, Michael J. Pishvaian, Ericka M. Ebot, Aatur D. Singhi, Ethan Sokol

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:

Εργαλεία αναζήτησης: